Omeros Corporation

Acucela Inc.

Ceptyr, Inc.

Jennifer Lynn Gage

Neil S Cutshall

Thomas L Little, Jr

Ian L Scott

Thomas Little

Mark W Orme

Vladimir Aleksandrovich Kuksa

Anna S Gall

Feng Hong

Thomas N Wheeler

Ryo Kubota

Peter Kurt Nollert Von Specht

Markus Metz

Sara Rebecca Goldstein

Do Yeon Kwon

Jennifer Tsoung

Santosh Kumar Keshipeddy

Robert Huerta Lemus

Qin Jiang

Lana Michele Rossiter

Jeremiah H Nguyen

Kevin F McGee, Jr

Michael Cicirelli

Sudheer Babu Vaddela

Wayne Douglas Luke

László Ürögdi

Karl Reineke

Elisabeth C A Brot

William C Patt

Maher Qabar

Mark Arnold Thomas Blaskovich

John E Bergmann

Hongkui Zeng

Gangadhar Nagula

Juhienah Khalaf

Rene Onrust

Ted Baughman

James Jeffry Howbert

Sándor Cseh

Michael James McDermott

Ákos Papp

Franz A Gruswitz

Vladimir Aleksandrovich Kuska

Loren Michael Price

Derek Johnston

Marco Jonas

Elisabeth Ca Brot

Thomas L Little

Michael James Mcdermott

Ekaterina Albert

Jennifer Leigh Nelson

Christopher Scott Seadeek

Xufeng Sun

Suba Iyer

Kevin L Harbol

Lauri Marie Schultz

Raghuram Bommagani

Durga Varaprasad Botla

Lauri Mario Schultz

Laxma Reddy Karnati

Satyamurthi Narayanan

Melinda Davis

Elisabeth CA Brot

Karl E Reineke

Neil Thomas Wheeler

Thomas Neil Wheeler

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

MASP-2 inhibitors and methods of use

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

Styrenyl derivative compounds for treating ophthalmic diseases and disorders

Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

PDE10 inhibitors and related compositions and methods

The invention relates to a novel variable hydrate crystalline form of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the inhibition of PDE10.

Solid state forms of a PDE10 inhibitor

Isolated or pure compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including but not limited to psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing an isolated or pure compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

The present invention is directed to an improved process for the preparation of compounds of Formula (II) and Formula (III), which are useful in the inhibition of PDE10. In particular, the present invention is directed to an improved process for the preparation of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, which is useful in the inhibition of PDE10.

Processes and intermediates for the preparation of a PDE10 inhibitor

Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.

Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders

Growing community of inventors

Kenmore, WA, United States of America

Jennifer Lynn Gage